SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

ODDITY Tech is experiencing a dramatic sell-off after guiding for a significant Q1 revenue drop due to a problematic advertising algorithm. The community is split, with many believing the stock is severely oversold given its cash-heavy balance sheet, while others remain skeptical about the business's outlook after management's unclear explanation of the issue.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending following fresh analyst upgrades with significant price targets and a strategic U.S. manufacturing partnership for its high-performance silicon anode batteries. The community is keenly focused on the company's pivotal role in the burgeoning drone and defense industries, where its superior battery technology is seen as a necessity for extended mission capabilities.

Equinox Gold Corp. is a growth-focused mining company, which engages in the exploration of gold mining properties. It operates through the following segments: Greenstone, Mesquite, Castle Mountain, Los Filos, Aurizona, Fazenda, RDM, Santa Luz, and Corporate. The company was founded by Marc Pais on March 23, 2007, and is headquartered in Vancouver, Canada.

Equinox Gold Corp

Equinox Gold is trending following the strategic sale of its Brazil operations for over $1 billion, a move largely seen as strengthening its balance sheet and focusing on North American growth with the recent first gold pour at its Greenstone Mine. Community discussion highlights analyst upgrades and high expectations for the company to achieve major gold producer status, despite some past frustration over share price performance.

ProShares Trust - ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF (VIXY) is trending as traders position for heightened market volatility, fueled by escalating geopolitical tensions and renewed threats of global tariffs. The community is actively discussing hedging strategies against perceived market complacency and the potential for significant downturns.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

SQD is a focal point of discussion following the rollout of its Tokenomics 2.0 and Revenue Pool, which aim to reduce supply and offer stablecoin rewards, as well as its strategic integration into Rezolve AI's ecosystem as a crucial blockchain data platform. The community is split, with strong bullish sentiment anticipating its role as a key data rail for AI contrasting with concerns over past price volatility and retail investor token utility.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is actively discussed following a robust earnings report and anticipation of new Navenibart data at upcoming healthcare conferences. This combination drives investor optimism about pipeline potential and fuels heated debates around high short interest and management's approach to shareholder value.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar (GSAT) is trending amidst escalating speculation of a potential buyout from major tech players like SpaceX or Amazon, leveraging its uniquely valuable n53 spectrum and deepening Apple partnership. The community is eagerly anticipating key FCC decisions regarding spectrum use and the deployment of Globalstar's C-3 constellation, seen as critical catalysts, while highlighting its foundational role in direct-to-device connectivity and emerging IoT solutions.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as optimistic projections for government contracts and strong January bookings, highlighted by the CEO's confident statements, clash with ongoing concerns about unprofitability and a high valuation in the speculative quantum computing sector.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is seeing heated discussion following its preliminary benchmark announcement for the Gemini-II AI chip, which proponents highlight for its edge AI efficiency and defense potential, while a significant portion of the community alleges misleading claims and market manipulation by the company and its promoters.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave (CRWV) is experiencing extreme volatility following its earnings report, which unveiled ambitious capital expenditure plans for 2026 amidst strong revenue growth and a substantial backlog. While some investors are concerned about increased debt and near-term profitability, others see the aggressive spending as a strategic move to capture surging AI infrastructure demand, supported by major industry investments, fueling a debate between short-term risks and long-term opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Syndax Pharmaceuticals Q4 Earnings Call Highlights

Syndax Pharmaceuticals (NASDAQ:SNDX) executives highlighted a transformational year in 2025 during the company's fourth-quarter earnings call, pointing to momentum from two commercial launches...

Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts...

Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of -21.88% and +10.21%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Insights into Syndax Pharmaceuticals Q4 Earnings

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve analysts that are covering the stock, Marketbeat.com reports. One...

Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Monday

Syndax Pharmaceuticals (NASDAQ:SNDX) will be releasing its Q4 2025 earnings before the market opens on Monday, March 2. (View Earnings Report at...

Aberdeen Group plc Grows Position in Syndax Pharmaceuticals, Inc. $SNDX

Aberdeen Group plc raised its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 22.9% in the third quarter, according to the company in its most recent disclosure with the...

Syndax Pharmaceuticals Highlights Revuforj, Niktimvo Sales Surge and 2026 Milestones at Guggenheim Conf

Syndax Pharmaceuticals (NASDAQ:SNDX) executives told investors at a Guggenheim biotech conference that the company entered 2026 with what CEO Michael Metzger called a fantastic start, pointing to...

Syndax Pharmaceuticals (NASDAQ:SNDX) CFO Sells $71,712.30 in Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) CFO Keith Goldan sold 3,410 shares of the firm's stock in a transaction on Monday, February 9th. The shares were sold at an average price...

Candriam S.C.A. Raises Holdings in Syndax Pharmaceuticals, Inc. $SNDX

Candriam S.C.A. lifted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 37.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm...

$SNDX Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.78 up 29.09% YoY
• Reported revenue of $68.73M up 794.90% YoY
• Syndax Pharmaceuticals expects to continue incurring significant losses for the near future as it advances commercialization and development activities, though existing cash and investments are projected to fund operations for at least the next 12 months.

Stocktwits

Syndax Pharmaceuticals Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$0.78 up 29.09% YoY
• Reported revenue of $68.73M up 794.90% YoY
• Syndax Pharmaceuticals expects to continue incurring significant losses for the near future as it advances commercialization and development activities, though existing cash and investments are projected to fund operations for at least the next 12 months.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

$SNDX Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.78 up 29.09% YoY
• Reported revenue of $68.73M up 794.90% YoY

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$0.78 up 29.09% YoY
• Reported revenue of $68.73M up 794.90% YoY

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Current Price	$21.71
Prev Close	$20.67
Open	$20.00
Dividend Yield	0.00%
50-Day Moving Average	$20.82
Beta	1.16
Avg. Volume	1.33M
PE Ratio	-5.72

52-Week High	$22.73
52-Week Low	$8.58
Market Capitalization	$1.8B
EPS (Annual)	-$3.72
Price to Book	15.56
Revenue Per Employee	$87,703.70

SNDX
Syndax Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SNDX News

SNDXSyndax Pharmaceuticals Inc